Am J Psychiatry 160:1830-1835, October 2003
© 2003 American Psychiatric Association
Pharmacogenetics of Antidepressant Medication Intolerance
Greer M. Murphy, Jr., M.D., Ph.D.,
Charlotte Kremer, M.D.,
Heidi E. Rodrigues, B.A., and
Alan F. Schatzberg, M.D.
OBJECTIVE: The authors sought to identify genetic markers for antidepressant medication intolerance. Genetic variation in drug metabolizing enzymes such as cytochrome P450 2D6 (CYP2D6) has been postulated to underlie antidepressant intolerance (pharmacokinetic effect). However, variation in genes encoding serotonin receptors could also explain antidepressant side effects (pharmacodynamic effect). METHOD: An 8-week, double-blind, randomized pharmacogenetic study compared the widely prescribed antidepressants paroxetine (a selective serotonin reuptake inhibitor [SSRI]) and mirtazapine (not an SSRI) in 246 elderly patients with major depression. Genotypes were determined for the 102 T/C single nucleotide polymorphism (SNP) in the serotonin 2A (5-HT2A) locus (HTR2A), previously associated with psychotropic medication treatment outcome. Oligonucleotide microarrays were used to extensively characterize variation in the CYP2D6 gene. Clinical outcomes included treatment discontinuations, adverse events, medication compliance, and change in mood. RESULTS: Survival analysis showed discontinuations due to paroxetine-induced side effects were strongly associated with the HTR2A C/C genotype. There was a significant linear relationship between the number of C alleles and the probability of discontinuation. Side effect severity in paroxetine-treated patients with the C/C genotype was also greater. In contrast, HTR2A 102 T/C genotype had no effect on mirtazapine side effects. CYP2D6 genotype did not predict treatment outcome for either medication. CONCLUSIONS: Pharmacodynamic differences among patients due to variant 5-HT2A receptors appear to be more important than pharmacokinetic variation in determining paroxetine intolerance. Pharmacogenetic markers may be useful in predicting antidepressant treatment outcome.
Related Article:
-
In This Issue
Am J Psychiatry 2003 160: A62.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
L. I. Sinclair, D. M. Christmas, S. D. Hood, J. P. Potokar, A. Robertson, A. Isaac, S. Srivastava, D. J. Nutt, and S. J. C. Davies
Antidepressant-induced jitteriness/anxiety syndrome: systematic review
The British Journal of Psychiatry,
June 1, 2009;
194(6):
483 - 490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Papakostas, C. Homberger, and M. Fava
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
J Psychopharmacol,
November 1, 2008;
22(8):
843 - 848.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Barbui MD, T. A. Furukawa MD, and A. Cipriani MD
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
Can. Med. Assoc. J.,
January 29, 2008;
178(3):
296 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Leckband, J. R. Bishop, and V. L. Ellingrod
Pharmacogenomics in Psychiatry
Journal of Pharmacy Practice,
June 1, 2007;
20(3):
252 - 264.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. H Perlis
Cytochrome P450 genotyping and antidepressants
BMJ,
April 14, 2007;
334(7597):
759 - 759.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frick, M. Roos, and K. Fattinger
How much is too much? Oligosymptomatic presentation after 11.5 g of diphenhydramine
Human and Experimental Toxicology,
February 1, 2007;
26(2):
131 - 133.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock
Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies
J Psychopharmacol,
July 1, 2006;
20(4_suppl):
33 - 40.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. M. Murphy Jr
Application of microarray technology in psychotropic drug trials
J Psychopharmacol,
July 1, 2006;
20(4_suppl):
72 - 78.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. N. Juurlink, M. M. Mamdani, A. Kopp, and D. A. Redelmeier
The Risk of Suicide With Selective Serotonin Reuptake Inhibitors in the Elderly
Am J Psychiatry,
May 1, 2006;
163(5):
813 - 821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Lotrich and B. G. Pollock
Aging and Clinical Pharmacology: Implications for Antidepressants
J. Clin. Pharmacol.,
October 1, 2005;
45(10):
1106 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R Shah
Pharmacogenetics in drug regulation: promise, potential and pitfalls
Phil Trans R Soc B,
August 29, 2005;
360(1460):
1617 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Grigorenko
The Inherent Complexities of Gene-Environment Interactions
J. Gerontol. B. Psychol. Sci. Soc. Sci.,
March 1, 2005;
60(suppl_Special_Issue_1):
53 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Shanahan and S. M. Hofer
Social Context in Gene-Environment Interactions: Retrospect and Prospect
J. Gerontol. B. Psychol. Sci. Soc. Sci.,
March 1, 2005;
60(suppl_Special_Issue_1):
65 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht
Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy
Clin. Chem.,
February 1, 2005;
51(2):
376 - 385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Schatzberg
Recent Studies of the Biology and Treatment of Depression
Focus,
January 1, 2005;
3(1):
14 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Murphy Jr, S. B. Hollander, H. E. Rodrigues, C. Kremer, and A. F. Schatzberg
Effects of the Serotonin Transporter Gene Promoter Polymorphism on Mirtazapine and Paroxetine Efficacy and Adverse Events in Geriatric Major Depression
Arch Gen Psychiatry,
November 1, 2004;
61(11):
1163 - 1169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht
Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers
Clin. Chem.,
September 1, 2004;
50(9):
1623 - 1633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. HARTTER
Genetics in Pharmacokinetics?
Am J Psychiatry,
July 1, 2004;
161(7):
1308 - 1309.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Malhotra, G. M. Murphy Jr., and J. L. Kennedy
Pharmacogenetics of Psychotropic Drug Response
Am J Psychiatry,
May 1, 2004;
161(5):
780 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Murphy, A. Lerner, G. Rudnick, and K.-P. Lesch
Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics
Mol. Interv.,
April 1, 2004;
4(2):
109 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
